Ocera Therapeutics (OCRX) 2.42 $OCRX Ocera to Present at

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 1:12 AM

Ocera Therapeutics (OCRX) 2.42 $OCRX

Ocera to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 3:05PM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Jefferies 2016 Healthcare Conference. Ocera's presentation will take place on Friday, June 10, 2016 at 11:30 AM Eastern Time.
OCRX: 2.42 (-0.17)

Ocera to Present at the 2016 BIO International Convention
GlobeNewswire - Thu May 26, 3:05PM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Gaurav Aggarwal, M.D., Chief Business Officer, will be presenting at the 2016 BIO International Convention being held at the Moscone Center in San Francisco, California from June 6-9, 2016. Ocera's presentation will take place on Wednesday, June 8, 2016 in Room 1 at 1:00 PM Pacific Time.
OCRX: 2.42 (-0.17)

Ocera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress
GlobeNewswire - Fri Apr 29, 8:05AM CDT
-- Company on target to complete enrollment in STOP-HE in the fourth quarter; approximately 165 patients enrolled to date --
OCRX: 2.42 (-0.17)

Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress(TM) 2016 of the European Association for the Study of the Liver (EASL)
GlobeNewswire - Fri Apr 15, 8:05AM CDT
Data establish ammonia-lowering properties of orally-administered OCR-002 in preclinical model of cirrhosis
OCRX: 2.42 (-0.17)

Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
GlobeNewswire - Mon Apr 11, 8:05AM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the publication of promising preclinical data related to the Company's investigational drug candidate ornithine phenylacetate, OCR-002. The paper, entitled "Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension" is published in the April 2016 issue of the Journal of Hepatology (http://www.journal-of-hepatology.eu/article/S0168-8278(15)00777-1/abstract).
OCRX: 2.42 (-0.17)

Ocera to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:25PM CDT
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the 15 Annual Needham Healthcare Conference being held at The Westin NY Grand Central Hotel in New York, New York from April 12-13, 2016. Ocera's presentation will take place on Wednesday, April 13, 2016 at 3:40 PM Eastern Time.
OCRX: 2.42 (-0.17)

LifeSci Capital Initiates Coverage of Ocera Therapeutics
ACCESSWIRE - Thu Mar 24, 8:58AM CDT
Developing Therapies for Serious Diseases with High Unmet Medical Need; Report Available Here: http://www.lifescicapital.com/equity-research/ocera/
OCRX: 2.42 (-0.17)

Gastroparesis Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts - Key Vendors: GlaxoSmithKline, Evoke Pharma, Ocera Therapeutics - Research and Markets
BusinessWire - Mon Mar 07, 12:04PM CST
Research and Markets (http://www.researchandmarkets.com/research/6bxkgx/gastroparesis) has announced the addition of the "Gastroparesis Global Clinical Trials Review, H2, 2015" report to their offering.
EVOK: 5.26 (-0.04), OCRX: 2.42 (-0.17), GSK: 40.93 (-1.13)

Ocera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 03, 8:05AM CST
-- Patient enrollment progressing in STOP-HE clinical trial of OCR-002; Company expects to complete enrollment in the fourth quarter of 2016 --
OCRX: 2.42 (-0.17)

Ocera to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 3:20PM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that the Company will be presenting at the 18 Annual BIO CEO & Investor Conference taking place February 8 - 9, 2016 at the Waldorf Astoria in New York, NY. Ocera's management will present at 10:00 AM ET on Tuesday, February 9, in the Conrad room in the conference's Orphan/Rare Diseases track.
OCRX: 2.42 (-0.17)

3 Sectors to Avoid as China Stock Market Takes a Bumpy Ride
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 3:53PM CST
This time not only did the Chinese investors suffer -- stakeholders all over the world felt the heat of this market slump.
ALNY: 63.17 (-2.24), BVN: 11.09 (-0.19), OCRX: 2.42 (-0.17), IPI: 1.27 (-0.08), MIND: 4.31 (+0.06), HELI: 3.67 (-0.33)

Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
GlobeNewswire - Fri Jan 08, 8:05AM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced further details from its Phase 1 study of oral formulations of OCR-002, ornithine phenylacetate, in healthy subjects. The Company plans to conduct additional Phase 1 testing after further formulation optimization.
OCRX: 2.42 (-0.17)

Ocera names Dr Stan Bukofzer as CMO
M2 - Fri Jan 08, 6:09AM CST
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Thursday the addition of Dr Stan Bukofzer as its chief medical officer.
OCRX: 2.42 (-0.17)

Ocera Appoints Dr. Stan Bukofzer as Chief Medical Officer
GlobeNewswire - Thu Jan 07, 3:05PM CST
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Dr. Stan Bukofzer as Chief Medical Officer. Dr. Bukofzer most recently served as Chief Medical Officer of Hospira, Inc., where he was responsible for providing strategic and operational direction for clinical development, pharmacovigilance and safety and medical affairs across Hospira's three business units.
OCRX: 2.42 (-0.17)

A Refreshing Outlook -- Comprehensive Research on AU Optronics, Ocera Therapeutics, Solar3D and SUPERVALU
ACCESSWIRE - Tue Dec 22, 7:28AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: AU Optronics Corp (NYSE: AUO), Ocera Therapeutics Inc. (NASDAQ: OCRX), Solar3D Inc. (NASDAQ: SLTD) and SUPERVALU Inc. (NYSE: SVU). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AUO: 2.77 (-0.08), SVU: 4.68 (-0.05), OCRX: 2.42 (-0.17), SLTD: 2.44 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rain Agent Vaults: Revolutionizing Payments with AI

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

ProBio, AbTis Forge Bond for Next-Gen Oncology ADCs

Deal or No Deal: ProBio's New Licensing Agreement In the ever-evolving realm of biopharmaceuticals, ProBio's recent handshake with South Korea's AbTis is stirring the pot. The shot-callers at ProBio are passing the baton to AbTis, giving them a crack at developing a thumping new therapeutic antibody asset aimed squarely at oncology targets. Pretty slick move if you ask...

Alogent's Unify Snags Award for Innovation and Impact

Innovation That Captures Attention Alogent sure did grab the spotlight with their Unify platform walking away with a Credit Union Times Luminaries Award. The name of the game here is deposit processing innovation—the kind of buzz that turns heads in the banking world. This recognition isn't just another plaque for the lobby; it's a testament to a significant stamp on...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

FirstDigital Expands Fiber Network in Utah and Arizona

Weaving a Web of Connectivity Let's talk about FirstDigital putting its shoulder to the wheel in Utah and Arizona. They're expanding their redundant fiber network to rope in more businesses under their umbrella of connectivity. This ain't just another dry IT endeavor—it's about building a safety net for our ever-connected world. The Stakes of Network Disruption You know...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Alyssa Bunch: Big Moves in Tennessee Real Estate

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Bakersfield Sees Spike in Crashes Post Time Change

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?

You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...

Zephyr's Alto Hood: Redefining Kitchen Versatility

An Artist in the Kitchen Who knew a kitchen hood could be a canvas, right? Zephyr, always a punch above the ordinary in kitchen design, has pulled another rabbit out of their hat with the Alto Wall Custom Hood. Forget blending in; this piece is about standing out and shouting style—all while keeping your cooking area fresh. Options Galore The Alto Hood isn't about...